Infliximab-related hepatitis: Discussion of a case and review of the literature

Stefano Mancini, Elisa Amorotti, Sarah Vecchio, Maurizio Ponz de Leon, Luca Roncucci

Research output: Contribution to journalArticlepeer-review


Despite its rarity, infliximab-related hepatitis constitutes a cutting edge and challenging problem. In December 2004, a drug warning was issued by the Food and Drug Administration to alert healthcare professionals to the risk of hepatotoxicity in course of infliximab therapy. Subsequently, several reports of probable infliximab hepatitis have been published and interest is growing in trying to elucidate the impact of these events on clinical practice. After discussing our case report, the main characteristics of infliximab-mediated liver injury are analyzed, coupled with a review of the medical literature. Infliximab seems to provoke both immunomediated and a direct liver injury, but how this latter happens remains unclear. Moreover, infliximab immunomediated liver dysfunction resembles that of autoimmune hepatitis type I, with elevation of antinuclear, anti-smooth muscle, anti-double-strand DNA antibodies, and a clear preference for female sex. Finally, a flow chart is proposed with the purpose to help clinicians in the management of patients who develop signs of liver dysfunction during treatment with infliximab.

Original languageEnglish
Pages (from-to)193-200
Number of pages8
JournalInternal and Emergency Medicine
Issue number3
Publication statusPublished - Jun 2010


  • Autoimmune liver diseases
  • Immunomediated hepatitis
  • Infliximab-related hepatitis
  • TNF blockers

ASJC Scopus subject areas

  • Emergency Medicine
  • Internal Medicine


Dive into the research topics of 'Infliximab-related hepatitis: Discussion of a case and review of the literature'. Together they form a unique fingerprint.

Cite this